Pharmaceutical

ORIN-1001 by Shanghai Fosun Pharmaceutical (Group) for Kidney Cancer (Renal Cell Cancer): Likelihood of Approval

ORIN-1001 is under clinical development by Shanghai Fosun Pharmaceutical (Group) and currently in Phase II for Kidney Cancer (Renal Cell Cancer).

Jul 7, 2023 - 20:00
ORIN-1001 is under clinical development by Shanghai Fosun Pharmaceutical (Group) and currently in Phase II for Kidney Cancer (Renal Cell Cancer).
Read the original article

Tags:

Previous Article

AMG-305 by Amgen for Breast Cancer: Likelihood of Approval

Next Article

CJ-15314 by HK inno.N for Atopic Dermatitis (Atopic Eczema): Likelihood of Approval

What's Your Reaction?

like

dislike

love

funny

angry

sad

wow

Related Posts

CMN-005 by CoImmune for Relapsed Chronic Lymphocytic Leukemia (CLL): Likelihood of Approval

CMN-005 by CoImmune for Relapsed Chronic Lymphocytic Le...

Sep 10, 2024

Orion gets grant for cyp11a1 inhibitors for treating pr...

Aug 23, 2024

Sutro strengthens its immuno-oncology pipeline with two new ADCs

Sutro strengthens its immuno-oncology pipeline with two...

Aug 12, 2023